TY - JOUR AU - Lushnikova, Anna A. AU - Onyan, Anastasia V. AU - Kostarev, Alexander V. AU - Kozhikhova, Kseniya V. AU - Andreev, Sergey M. AU - Moiseeva, Natalya I. PY - 2019/11/06 Y2 - 2024/03/28 TI - Cell Viability Reducing In Doxorubicin-Resistant Breast Cancer by Cationic Peptides JF - RA Journal Of Applied Research JA - rajar VL - 5 IS - 11 SE - Articles DO - 10.33826/rajar/v5i11.02 UR - http://rajournals.in/index.php/rajar/article/view/552 SP - 2582-2585 AB - <p>Acquired resistance to various drugs is an obstacle for anticancer therapy. Doxorubicin (Dox)&nbsp; is the first-line chemo-drug for therapy of various malignant tumors but it fails when treatment of multi-drug resistant tumors. One of the main factors of&nbsp; Dox-resistance is over expression of drug resistance genes, particularly, P-glycoprotein – Pgp. Earlier we’ve revealed a high selective apoptosis of tumor cells, induced by some cationic peptides&nbsp; (CPs) <em>in vitro</em> through inactivation their cell targets – chaperone proteins nucleolin/NCL and nucleophosmin/NPM. This paper describes effect of CPs on breast cancer (BC) cell line HBL 100 and doxorubicin-resistant cell line HBL-100/Dox.</p><p><strong>Objective </strong>is to examine the viability of BC and Dox-resistant BC cells after incubation with CPs.</p><p><strong>Results</strong> Some Arg/Lys-enriched cationic peptides under study&nbsp; induce cell death by nucleolar stress initiation both in HBL 100 BC cell line and HBL 100/ID 120 one. Thus, these CPs are expected NCL/NPM inhibitors, which&nbsp; &nbsp;significantly reduce viability both BC and BC doxorubicin –resistant cells in vitro.</p> ER -